NYAGIM Event: Nanome
Details
Steve McCloskey, Carla Gauss, and Jonathon Gast will present: "Redefining Visualization and Collaboration through Virtual Reality"
We will hold the event online, starting at 6 pm with Nanome's presentation and Q&A, followed by some time for networking in Zoom breakout rooms for those who can stay and who would like to catch up with the community.
ABSTRACT
Please join us for a presentation and Q&A by Nanome CEO Steve McCloskey and application scientists Carla Gauss and Jonathon Gast. Nanome is a virtual reality platform for molecular modeling and structure-based drug design. Nanome's mission is to accelerate research and development by giving scientists a powerful collaborative, integrated, and intuitive R&D tool.
Steve McCloskey, CEO and Co-Founder at Nanome, will give an overview of Nanome and demonstrate why top pharmaceutical companies use Nanome to accelerate their drug discovery workflows.
Carla Gauss, PhD, Senior Application Scientist (Medicinal Chemistry) at Nanome, will cover how Nanome can be used to examine the X-Ray structures (PDB ID’s: 4CI1, 4CI2, and 6H0F) of three related immunomodulatory drugs: thalidomide, lenalidomide, and pomalidomide in complex with DDB1-cereblon E3 ubiquitin ligase in VR. A team of drug discovery scientists can then view and interact with the protein degrader complexes in real-time, fostering novel collaboration, ideas, and discoveries
Jonathon Gast, PhD, Application Scientist (Medicinal Chemistry) at Nanome, will cover how Nanome was used in structure-based drug design approaches against SARS-CoV2 targets. Nanome partnered with Engineering for Change (E4C) to discover novel binding pockets in NSP12, the main protease for drug repositioning. Additionally, Nanome was utilized to refine the selection of AI-derived small molecules created by InSilico to target the RNA-dependent RNA polymerase NSP5a.
We hope you can join our presentation and look forward to your questions.